See analyst estimates and all valuation multiples for Drug Delivery Systems
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $22.3B | 10.0x | 45.0x | |
| $6.9B | 5.5x | 23.1x | |
| $4.4B | 3.9x | 14.6x | |
| $3.8B | 16.4x | 52.6x | |
| $2.7B | n/a | n/a | |
| $2.5B | 19.9x | -2.4x | |
| $1.3B | 51.3x | n/a | |
| $1.3B | 4.2x | n/a | |
| $1.0B | 11.6x | -18.2x | |
| $851M | 13.8x | -4.5x | |
| $600M | 26.2x | -100.3x | |
| $539M | n/a | n/a | |
| $438M | 7.6x | 57.4x | |
| $270M | 71.8x | -1.6x | |
| $204M | 20.1x | -95.2x | |
| $177M | 5.1x | -8.3x | |
| $143M | n/a | n/a | |
| $140M | 1.6x | n/a | |
| $132M | n/a | n/a | |
| $123M | n/a | -4.2x | |
| $117M | 6.0x | -46.9x | |
| $106M | 2.7x | 5.9x | |
| $100M | n/a | n/a | |
| $99.7M | 2.0x | -1.8x | |
| $89.3M | 493.2x | n/a | |
| $62.6M | n/a | n/a | |
| $59.7M | 10.9x | n/a | |
| $51.0M | 11.8x | -2.3x | |
| $47.1M | 34.6x | -1.5x | |
| $41.9M | 8.2x | -9.0x | |
| $35.4M | n/a | n/a | |
| $31.9M | 49.7x | n/a | |
| $26.6M | 34.4x | -0.5x | |
| $22.2M | n/a | n/a | |
| $19.9M | n/a | n/a | |
| $17.0M | n/a | n/a | |
| $15.4M | n/a | n/a | |
| $14.7M | 32.2x | n/a | |
| $14.3M | n/a | -0.9x | |
| $12.7M | 2.0x | n/a | |
| $12.2M | 5.1x | n/a | |
| -$0.7M | n/a | n/a | |
| -$4.1M | -0.5x | n/a | |
| -$7.5M | -0.0x | n/a | |
| -$49.6M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Drug Delivery Systems